Holen Sie sich die Stockscreener-App
1.32
3.65%
-0.05
Schlusskurs vom Vortag:
$1.37
Offen:
$1.37
24-Stunden-Volumen:
271.07K
Relative Volume:
0.91
Marktkapitalisierung:
$23.76M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.29M
KGV:
-1.8857
EPS:
-0.7
Netto-Cashflow:
$-6.47M
1W Leistung:
+18.92%
1M Leistung:
-21.43%
6M Leistung:
-13.73%
1J Leistung:
-10.81%
1-Tages-Spanne:
$1.2834
$1.40
1-Wochen-Bereich:
$1.10
$1.49
52-Wochen-Spanne:
$0.94
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Firmenname
NanoViricides Inc
Sektor
Branche
Telefon
203-937-6137
Adresse
1 Controls Drive, Shelton, CT
Vergleichen Sie NNVC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.32 | 24.66M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2015-02-11 | Eingeleitet | Midtown Partners | Strong Buy |
NanoViricides Inc Aktie (NNVC) Neueste Nachrichten
Is Steel Dynamics Stock Outperforming the Dow? - Barchart.com
Is PTC Stock Underperforming the Nasdaq? - Barchart.com
Is Teradyne Stock Outperforming the Nasdaq? - Barchart.com
Is Cardinal Health Stock Outperforming the Nasdaq? - Barchart.com
How Is Rollins’ Stock Performance Compared to Other Cyclical Stocks? - Barchart.com
GBPUSD Extends Rally As Bullish Impulse Builds - Barchart.com
Apple Stock Marks a Solid Comeback. Is AAPL a Buy, Sell, or Hold for 2026? - Barchart.com
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Enterprise News
Why Are Revolve (RVLV) Shares Soaring Today - Barchart.com
Upwork (UPWK) Stock Is Up, What You Need To Know - Barchart.com
This Clinical-Stage Biotech Just Raised $6M to Advance a Drug That Could Address Pandemic Preparedness Gaps - Barchart.com
DiagnosTear Technologies Inc.Confirmation of No Material Change - Barchart.com
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - Livingston Daily
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - Reuters
NanoViricides Inc Stock Analysis and ForecastGlobal Trade Effects & Free Get Breakthrough Ideas - earlytimes.in
Upstart (UPST): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
Oracle Earnings: What To Look For From ORCL - Barchart.com
Stocks in play: Aurora Cannabis Inc. - Barchart.com
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - Victorville Daily Press
Is Monolithic Power Systems Stock Outperforming the Nasdaq? - Barchart.com
Why NanoViricides Inc. (NV3P) stock attracts wealthy investorsPortfolio Performance Report & Reliable Entry Point Trade Alerts - Newser
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Lansing State Journal
How NanoViricides Inc. stock compares with tech leadersEarnings Risk Report & Technical Confirmation Alerts - Newser
Why institutional investors increase stakes in NanoViricides Inc. (NV3P) stockMarket Activity Report & High Accuracy Investment Signals - Newser
Can NanoViricides Inc. stock survive global slowdownWeekly Investment Report & Verified Entry Point Signals - Newser
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd - The Ames Tribune
Will NanoViricides Inc. (NV3P) stock announce a stock split2025 Dividend Review & Technical Confirmation Trade Alerts - Newser
Will NanoViricides Inc. (NV3P) stock outperform energy sector in 2025Weekly Trade Review & Smart Investment Allocation Tips - Newser
How NanoViricides Inc. stock trades after earningsTrend Reversal & Reliable Trade Execution Plans - Newser
Is NanoViricides Inc. stock a buy before earnings resultsMarket Growth Report & Long-Term Capital Growth Ideas - Newser
Is NanoViricides Inc. stock a defensive play amid uncertaintyWeekly Risk Summary & Weekly High Potential Stock Alerts - Newser
Will NanoViricides Inc. (NV3P) stock profit from AI boomEarnings Miss & AI Forecast Swing Trade Picks - Newser
NanoViricides (NYSE:NNVC) Stock Price Down 8.2% – What’s Next? - Defense World
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - Gadsden Times
Why Strategy (MSTR) Stock Is Up Today - Barchart.com
Is Johnson Controls International Stock Outperforming the Nasdaq? - Barchart.com
Can NanoViricides Inc. (NV3P) stock ride next bull market cycle2025 Technical Overview & Low Volatility Stock Recommendations - Newser
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Worcester Telegram
NanoViricides Partners with Regulatory Consultant to Pursue Orphan Drug Status for Broad-Spectrum Antiviral NV-387 - citybuzz
NanoViricides inks regulatory services deal to advance orphan drug strategy for antiviral NV-387 - Proactive financial news
Nanoviricides signs agreement for orphan drug strategy of NV-387 for mpox, smallpox, and measles - marketscreener.com
NanoViricides (NNVC) engages Only Orphans Cote for NV-387 orphan path at FDA - Stock Titan
Finanzdaten der NanoViricides Inc-Aktie (NNVC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):